Bristol-Myers Squibb Company
ANTICANCER COMBINATION THERAPY WITH CD73 ANTAGONIST ANTIBODY AND PD-1/PD-L1 AXIS ANTAGONIST ANTIBODY
Last updated:
Abstract:
Provided herein are methods for treating cancer, comprising administering to a subject having cancer a therapeutically effective amount of a CD73 antagonistic antibody alone or in combination with a PD-1/PD-L1 axis antagonist antibody.
Status:
Application
Type:
Utility
Filling date:
12 Apr 2019
Issue date:
20 May 2021